XML 66 R50.htm IDEA: XBRL DOCUMENT v3.22.4
Acquisitions (Narrative) (Details)
$ / shares in Units, $ in Millions
1 Months Ended 12 Months Ended
Jan. 22, 2021
USD ($)
Dec. 31, 2022
USD ($)
right
$ / shares
Jan. 31, 2021
USD ($)
right
$ / shares
Feb. 29, 2020
USD ($)
Dec. 31, 2022
USD ($)
$ / shares
Dec. 31, 2021
USD ($)
Dec. 31, 2020
USD ($)
Dec. 01, 2022
USD ($)
Business Acquisition [Line Items]                
Acquired in-process research and development and development milestones         $ 908.5 $ 970.1 $ 769.8  
Cash paid, net of cash acquired         327.2 747.4 849.3  
Goodwill   $ 4,073.0     4,073.0 3,892.0    
Repayments of long-term debt         1,560.0 $ 1,905.4 $ 276.5  
Acquired IPR&D Expense         $ 333.8      
Akouos Acquisition                
Business Acquisition [Line Items]                
Business acquisition, share price (in dollars per share) | $ / shares   $ 12.50     $ 12.50      
Cash paid, net of cash acquired   $ 327.2            
Consideration transferred, number of contingent value rights | right   1            
Contingent value right, additional price per share (in dollars per share) | $ / shares   $ 3.00     $ 3.00      
Contingent value right, additional price per share, aggregate amount   $ 122.0     $ 122.0      
Goodwill               $ 181.2
Acquired IPR&D               $ 184.0
Prevail Therapeutics Inc.                
Business Acquisition [Line Items]                
Business acquisition, share price (in dollars per share) | $ / shares     $ 22.50          
Cash paid, net of cash acquired $ 747.4   $ 747.4          
Consideration transferred, number of contingent value rights | right     1          
Contingent value right, additional price per share (in dollars per share) | $ / shares     $ 4.00          
Contingent value right, additional price per share, aggregate amount     $ 160.0          
Contingent value right, monthly reduction | $ / shares     $ 0.083          
Goodwill 126.8              
Acquired IPR&D 824.0              
Deferred tax liabilities $ 106.0              
Dermira                
Business Acquisition [Line Items]                
Consideration transferred       $ 849.3        
Goodwill       86.8        
Acquired IPR&D       1,200.0        
Deferred tax liabilities       49.5        
Long-term debt assumed       375.5        
Repayments of long-term debt       $ 276.2